[Therapeutic effect of ceftizoxime on infection in patients with lung cancer].
Ceftizoxime (CZX) was given in daily doses of 4 approximately 6 g by intravenous drip infusion to 30 patients with infection accompanying lung cancer to investigate the usefulness of the drug for infectious disease: The rate of effectiveness (marked and moderate) was 73.3% (22/30 patients). Of the 30 patients, 2 had drug fever; 1, arthralgia; and 1, eosinophilia. These side effects improved after the drug was withdrawn. CZX is a very useful antibiotic with high effectiveness and safety in immunocompromised patients with infection accompanying advanced lung cancer.
D000236:Adenoma / Q000150:complications; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D018288:Carcinoma, Small Cell / Q000150:complications; D002294:Carcinoma, Squamous Cell / Q000150:complications; D002439:Cefotaxime / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015296:Ceftizoxime; D005260:Female; D005334:Fever / Q000139:chemically induced; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications*; D008297:Male; D008875:Middle Aged; D011014:Pneumonia / Q000188:drug therapy; D011702:Pyelitis / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy
D015296:Ceftizoxime; D002439:Cefotaxime